US20120027836A1 - Novel edwardsiella ictaluri e-ict-vl33 strain, vaccines thereof, and a method for protecting fishes using said vaccines - Google Patents

Novel edwardsiella ictaluri e-ict-vl33 strain, vaccines thereof, and a method for protecting fishes using said vaccines Download PDF

Info

Publication number
US20120027836A1
US20120027836A1 US13/050,453 US201113050453A US2012027836A1 US 20120027836 A1 US20120027836 A1 US 20120027836A1 US 201113050453 A US201113050453 A US 201113050453A US 2012027836 A1 US2012027836 A1 US 2012027836A1
Authority
US
United States
Prior art keywords
strain
ict
ictaluri
fish
immersion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US13/050,453
Other versions
US8114411B1 (en
Inventor
Tsun-Yung Kuo
Hsu Chung Gabriel Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SBC Virbac Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US13/050,453 priority Critical patent/US8114411B1/en
Priority to US13/314,724 priority patent/US8545852B2/en
Publication of US20120027836A1 publication Critical patent/US20120027836A1/en
Application granted granted Critical
Publication of US8114411B1 publication Critical patent/US8114411B1/en
Assigned to SBC VIRBAC LIMITED reassignment SBC VIRBAC LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHWEITZER BIOTECH COMPANY LTD.
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Definitions

  • the invention relates to a novel Edwardsiella ictaluri E-ict-VL33 strain, vaccines derived therefrom, and a method for protecting fishes using said vaccines.
  • Edwardsiella is a type of small Gram-negative rod bacterium.
  • the host of Edwardsiella includes Catfish, Eel, Tilapia and other warm water fishes.
  • Edwardsiella ictaluri is one member of Edwardsiella. E. ictaluri that can infect catfish, thereby causing Edwardsiella septicemia.
  • Acute Edwardsiella septicemia usually results in typical bacterial septicemia with a high mortality rate for fishes.
  • Chronic Edwardsiella septicemia can result in Hole-in-the-head syndrome, septicemia or, ultimately, death.
  • Edwardsiella septicemia occurs worldwide and causes high mortality and considerable economic damage to the catfish industry, especially in Vietnam and the USA.
  • Microbiological infections with E. ictaluri play a major role in catfish ( Pangasianodon hypophthalmus ) farming in Vietnam [Dung T T, et al., Microbe Drug Res 2008.] and were first observed in the Mekong River Delta in 1999 [Ferguson H W, et al. J Fish Dis 2001; 24:509-13].
  • E. ictaluri infections are seen in the USA in channel catfish ( Ictalurus punctatus ) and also in walking catfish in Thailand [Kasornchandra J, et al. J Fish Dis 1987; 10:137-8]. All catfish species are susceptible to E. ictaluri and the disease causes major damage in Basa Tra fish in the Mekong delta and other places where the fish is cultured in Vietnam. Many ways of protecting the fish have been tried but none so far have been very successful.
  • Vaccination as a preventive measure to control infections with E. ictaluri has been tried in various catfish species. Until now, not a single vaccination or combination of vaccinations has been proven as particularly successful in the field. It has been claimed that an attenuated vaccine is able to help in the control of the disease but, to date, the product has not made major inroads in the field. Besides that, oral delivery of vaccine antigens to fish is the preferred method for several reasons. However the limitations of this method include lack of immune efficacy [Gudding R, et al. Vet Immunol Immunopathol 1999].
  • the inventor had developed a novel Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines.
  • One object of the invention is to provide a novel Edwardsiella ictaluri E-ict-VL33 strain, which had been identified as a novel strain of E. ictaluri.
  • Another object of the invention is to provide a vaccine, which is prepared from the inactivated E. ictaluri E-ict-VL33 strain.
  • Said vaccine can be prepared as an immersion form, oral form or other suitable form.
  • Still another object of the invention is to provide a method for improving the immunity of fish against E. ictaluri , and further preventing and protecting fishes from infection of E. ictaluri by using said vaccines.
  • the invention comprises various aspects as will be discussed below.
  • a novel E. ictaluri E-ict-VL33 strain is to be provided.
  • This strain was isolated from infected tra catfish ( Pangasius hypophthalmus ).
  • the isolated E-ict-VL33 strain has been cultured and identified as a novel E. ictaluri strain, named E. ictaluri E-ict-VL33, and deposited in the biological resource center ATCC Patent Depository, located at 10801 University Boulevard., Manassas, Va. 20110 on Mar. 8, 2010, with an ATCC deposit number PTA-10711 and identification reference by deposit Edwardsiella ictaluri : E-ict-VL33.
  • the bacterium strain of the invention has been used herein is an example, but the invention will not be limited thereto as all kinds of suitable strains are comprised in the invention.
  • the invention provides a vaccine composition comprising said novel E. ictaluri strain.
  • said vaccine composition is a vaccine.
  • the vaccine comprises an effective amount of inactivated E. ictaluri E-ict-VL33 strain and a pharmaceutically acceptable vehicle. It can be prepared in any dosage form suitable for the invention.
  • Said suitable form of the invention includes, but is not limited to, oral-form, immersion-form, injection-form or other suitable forms for the invention.
  • An immersion vaccine is obtained by using an inactivating agent to inactivate or kill the E. ictaluri E-ict-VL33 strain (i.e., an inactivation process).
  • the inactivated bacteria is then suspended in a buffer solution. This process allows an immersion vaccine to be obtained.
  • An oral vaccine is obtained by using an inactivating agent to inactivate or kill the Edwardsiella ictaluri E-ict-VL33 strain (i.e., an inactivation process).
  • the inactivated bacteria is then suspended in a buffer solution to form a bacterial suspension, and the bacterial suspension is mixed with an adjuvant to form a mixture.
  • the mixture is then homogenously emulsified by a homogenizer with high shear force.
  • Said oral vaccine can further be spray coated on the outside of a feed to deliver the oral vaccine to fish.
  • the coated feed can further be sprayed with edible oil, such as plant oil and/or animal oil (in particular, a fish oil), to improve the delivery efficiency of the oral vaccine.
  • inactivation includes, but is not limited to, treatment with inactivation agent, heat treatment, and other general methods to inactivate or kill the bacteria.
  • the inactivation agent includes, but is not limited to, formaldehyde, binary ethyleneimine (BEI) or other suitable inactivation agents.
  • the pharmaceutically acceptable vehicle includes, but is not limited to, solvent, emulsifier, suspending agent, decomposer, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, surfactant, adjuvant or other suitable vehicle.
  • the adjuvant includes, but is not limited to, oleaginous adjuvant (such as mineral oil, plant oil, animal oil, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, etc.), aqueous adjuvant (such as aluminum hydroxide), two-phase oleaginous adjuvant (such as water/oil/water form (w/o/w)) etc, and biological (such as adjuvant oligonucleotide and toxoid).
  • the two-phase oleaginous adjuvant comprises a surfactant and an oleaginous substance.
  • the surfactant is selected from the group consisting of: at least one of sorbitol fatty acid ester, the concentrate of sorbitol fatty acid ester and ethylene oxide (or propylene oxide), mannitol fatty acid ester, the concentrate of mannitol fatty acid ester and ethylene oxide (or propylene oxide), modified mannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; anhydromannitol fatty acid ester, modified anhydromannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; saccharose fatty acid ester, the concentrate of saccharose fatty acid ester and ethylene oxide (or propylene oxide), glycerol fatty acid ester, the concentrate
  • the invention also provides a composition comprising the novel E. ictaluri strain.
  • the composition can be applied to various suitable products such as challenge composition containing live bacteria, vaccine containing inactivated bacteria etc.
  • the invention provides a method for improving the immunity of fishes against E. ictaluri , further preventing and protecting fishes from infection of E. ictaluri by using said vaccines.
  • a method comprising a primary immunization by immersion vaccination at first and, after an appropriate time period, a subsequent oral vaccination boosting, can give a protecting effect higher than would be obtained by other vaccination routes.
  • fishes refer to those that are susceptible to Edwardsiella ictaluri infection, in particular, catfishes.
  • the invention also provides the use of Edwardsiella ictaluri E-ict-VL33 in preparation of a vaccine to protect fish from infection of Edwardsiella ictaluri.
  • the term “effective amount” refers to the amount of inactivated bacteria used to improve the immunity of fish against E. ictaluri , and then the amount of inactivated bacteria used to prevent and protect the fish from the infection of E. ictaluri or disease derived thereto in further inoculation.
  • prevent and protect is intended to mean that, compared to the immunity of untreated fish, the immunity of treated fish against E. ictaluri is improved and the survival rate of treated fish after infection of E. ictaluri is higher than survival rate of untreated fish. Further inoculation of the amount of inactivated bacteria prevents and protects the fish from the infection of E. ictaluri or disease derived thereto.
  • FIG. 1 shows the morphology of the novel Edwardsiella ictaluri E-ict-VL33 strain under microscope.
  • FIG. 2 shows the cumulative mortality (%) obtained after challenge performed at 48 days post-vaccination using an immersion challenge in Groups A, C and E.
  • FIG. 3 shows the cumulative mortality (%) obtained after immersion challenge at 121 days post-primary immunization for Groups A, C, E and F.
  • E-ict-VL33 strain was isolated from infected tra catfish ( P. hypophthalmus ). Bacterial culture grown in Brain Heart Infusion (BHI, the composition of BHI are shown in Table 1) broth for 18 hours at 25-30° C. was used for experimental infection. Bacteria growth on BHI agar for 48 h at 30° C. was used for bacterial identification.
  • BHI Brain Heart Infusion
  • composition of BHI broth (Difco Laboratories, Sparks, MD) Composition Content Calf Brains, Infusion from 200 g 7.7 g Beef Heart, Infusion from 250 g 9.8 g Proteose Peptone 10.0 g Dextrose 2.0 g Sodium Chloride 5.0 g Disodium Phosphate 2.5 g Add water up to 1 liter Total 1 liter
  • FIG. 1 shows that the isolated E-ict-VL33 strain is a rod bacterium.
  • An analysis of Gram staining shows that the isolated E-ict-VL33 strain is a Gram-negative rod bacterium.
  • Tables 2 to 4 show the growth situation of the isolated E-ict-VL33 strain under different culture conditions such as different temperature, salinity or pH value. “+” represents that the growth of bacteria is slower and contains a lower concentration of bacteria. “++” represents that the bacteria have grown with less precipitation. “+++” represents that the bacteria have grown with higher precipitation. “ ⁇ ” represents that there no growth of bacteria can be observed.
  • the isolated E-ict-VL33 strain can be cultured in a tryptic soy broth (TSB) or a brain heart infusion (BHI).
  • TLB tryptic soy broth
  • BHI brain heart infusion
  • Table 5 shows the carbohydrate metabolism performance of the isolated E-ict-VL33 strain. “+” represents that the carbohydrate can be metabolized by the isolated E-ict-VL33 strain.
  • E. ictaluri strains have a PEI1 plasmid
  • the inventor used the ORF1 (open reading frame 1) of the PEI1 plasmid (GenBank accession no: AF244083.1) of an E. ictaluri strain as a template to design PCR primers. Sequence of the PEI1 plasmid of the isolated E-ict-VL33 strain was determined by PCR using said primers. After sequencing, a partial sequence of the PEI1 plasmid of the isolated E-ict-VL33 strain is shown in SEQ ID No: 2 (the length of SEQ ID No: 2 is 1876 bp).
  • the result indicates that the fragment of the 1 st nucleotide (nt) to the 1443 rd nt of SEQ ID NO: 2 is similar with the sequence of the PEI1 plasmid (GenBank accession no: AF244083.1) with 99% identity. However, the fragment of the 1444 th nt to the 1876 th nt of SEQ ID NO: 2 is different from the sequence of the PEI1 plasmid (GenBank accession no: AF244083.1). This indicates that the isolated E-ict-VL33 strain is different from the E.
  • the isolated E-ict-VL33 strain and the E. ictaluri strain with the PEI1 plasmid are both E. ictaluri , they are different strains according to the sequencing result. Therefore, the isolated E-ict-VL33 strain is a novel E. ictaluri isolated strain.
  • the result shows that the isolated Edwardsiella ictaluri E-ict-VL33 strain is identified as a novel Edwardsiella ictaluri strain, and the E-ict-VL33 strain has been deposited in the ATCC on Mar. 8, 2010, with an ATCC deposit number PTA-10711.
  • the bacteria ( Edwardsiella ictaluri E-ict-VL33 strain) were cultured in Brain Heart Infusion (BHI) broth at 28° C. for 48 hours, then collected in a bacteria suspension.
  • BHI Brain Heart Infusion
  • Inactivation of bacteria was done by adding 37% formaldehyde at a final concentration of 0.5% (w/v) to the bacteria suspension obtained in Example 1, and incubating (shaking) the bacteria suspension with formaldehyde at 25° C., 70 rpm for a minimum of 24 hours (preferably 48 hours).
  • the bacteria Edwardsiella ictaluri E-ict-VL33 strain
  • the supernatant of the bacteria suspension containing the formaldehyde was separated by using centrifugation at 9000 ⁇ g to remove the formaldehyde, then suspending the pellet in a buffer solution (such as distilled water, phosphate buffered saline (PBS)).
  • a buffer solution such as distilled water, phosphate buffered saline (PBS)
  • Vaccine stock obtained in example 2 were prepared as immersion vaccine by suspending the vaccine stock in a buffer solution (such as sterile water or PBS).
  • a buffer solution such as sterile water or PBS.
  • the content of formaldehyde in the immersion vaccine is lower than 0.2% (v/v).
  • Vaccine stock obtained in example 2 were prepared as a 400 liter oral vaccine by mixing 300 liters of vaccine stock (at least comprising 1.65 ⁇ 10 15 cfu bacteria), 4 liters of surfactant (polysorbate 80), and 96 liters of fish oil.
  • the antigen of E. ictaluri was coated with a two phase oleaginous adjuvant in a w/o/w form by homogenously emulsifying the mixture with a homogenizer with high shear force (10,000 rpm).
  • the oral vaccine can then be obtained.
  • the 400 liter oral vaccine is composed of 24% (v/v) fish oil, 1% (v/v) surfactant, and 3.85 ⁇ 10 8 cfu/ml inactivated bacteria.
  • the content of formaldehyde in the oral vaccine is lower than 0.2% (v/v).
  • the invention also provides the application of the oral vaccine obtained in example 4.
  • the oral vaccine can further be spray coated on the outside of commercially available pelleted feed at 2% (volume/weight). Also, the coated pellet can further be sprayed with squid oil at 0.1% (v/w).
  • the feed can be AQUAXCEL 7434 pelleted feed or other commercially available feed.
  • Healthy, non-infected, catfish P. hypophthalmus
  • Tra fish were vaccinated using immersion or oral vaccination or combinations of these vaccinations.
  • the various vaccinations or vaccination combinations and challenge preparation were divided into various experiments for the (sub) groups.
  • the various vaccinations or vaccination combinations and challenges were performed in at least 3 different experiments.
  • a total of about 1500 fish were used to set up the challenge model to be used in the trial.
  • Bath challenge Fifty fish per tank in three parallel tanks per dose (with 4 doses total) were challenged by pouring bacteria grown in BHI broth into water to give a final concentration of 5.5 ⁇ 10 3 to 5.5 ⁇ 10 6 colony forming units (5.5 ⁇ 10 3 , 5.5 ⁇ 10 4 , 5.5 ⁇ 10 5 and 5.5 ⁇ 10 6 ) of E. ictaluri E-ict-VL33 strain per ml of water. Exposure to the challenge dose lasted for 30 min. Strong aeration was supplied to the water in the tanks during the challenge. The control groups were immersed in clean aerated water. Mortalities were monitored for 14 days.
  • Injection challenge Before injecting, fish were anaesthetized with 0.2% MS222 in the water. Fish were injected intraperitoneally with 0.1 ml of a bacterial dilution at 4 different bacterial concentrations ranging from 5.5 ⁇ 10 3 to 5.5 ⁇ 10 6 colony forming units (10-fold steps, 5.5 ⁇ 10 3 , 5.5 ⁇ 10 4 , 5.5 ⁇ 10 5 and 5.5 ⁇ 10 6 ) of E. ictaluri per ml or sterile saline water for control. Mortalities were monitored for 14 days.
  • Group E oral-prime was given primary immunization at days 8 to 21 by the oral route and challenged at 48 and 121 days after primary vaccination.
  • Table 6 outlines how the immersion and oral vaccination of the various fish was done and which groups were challenged using the method established in Experiment 1.
  • Immersion vaccination The immersion vaccine consisted of a sterile water-based, killed bacterial suspension of 5.0 ⁇ 10 9 bacteria per ml Immersion vaccination was performed by immersing 1200 fish in 2 L of vaccine stock diluted in 18 L (5.56 ⁇ 10 8 bacteria per ml final concentration) of clean water for 1 min with strong aeration.
  • Oral vaccination The outside of feed pellets was spray coated by the oral vaccine obtained in Example 4 (in a w/o/w form, containing 3.85 ⁇ 10 8 cfu/ml) at 2% (volume/weight). The coated pellets were then sprayed with squid oil at 0.1% (v/w). The coated feed pellets were prepared daily and used within 1 to 2 days after preparation and fed to satiation.
  • the feed can be WOOSUNGVINA Co. J3, J4 feed or other commercially available feed.
  • Immersion challenge The immersion challenge was performed in 96 liter tanks containing 70 liters of clean water. At the first challenge (day 48), 40 or 50 fish (number of fish depending on the experiment) from each tank were transferred to a bucket containing 10 liter of clean water and then bacteria grown in BHI broth was poured into the water to given concentrations of 7.6 ⁇ 10 6 or 4.3 ⁇ 10 6 bacteria/ml of water for Experiments 2 and 3, respectively. Exposure to the challenge dose lasted for 1 h. At the second challenge (121 days), the same immersion method was applied with a concentration of 8.1 ⁇ 10 6 bacteria/ml of water for Experiments 2. The non-challenged controls were immersed in clean aerated water. After challenge the fish were observed for 14 days.
  • Relative Percent Survival(RPS) (1 ⁇ (% mortality in vaccinated fish/% mortality in control)) ⁇ 100.
  • the invention provides:
  • Vaccines derived from the novel Edwardsiella ictaluri E-ict-VL33 strain.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Fodder In General (AREA)

Abstract

A novel Edwardsiella ictaluri E-ict-VL33 strain, a vaccine derived from the novel Edwardsiella ictaluri E-ict-VL33 strain, especially in immersion form and oral form, and a method for protecting fishes from the infection of Edwardsiella ictaluri, especially catfish, the method including a primary immersion immunization using immersion vaccine, and after an appropriate period, boosting by oral vaccination, resulting in a strong and long-lasting immunity for fishes.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • The present application is a divisional application of U.S. patent application Ser. No. 12/845,965 filed on Jul. 29, 2010, which is incorporated by reference herein in its entirety.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The invention relates to a novel Edwardsiella ictaluri E-ict-VL33 strain, vaccines derived therefrom, and a method for protecting fishes using said vaccines.
  • 2. Brief Description of the Prior Art
  • Edwardsiella is a type of small Gram-negative rod bacterium. The host of Edwardsiella includes Catfish, Eel, Tilapia and other warm water fishes. Edwardsiella ictaluri is one member of Edwardsiella. E. ictaluri that can infect catfish, thereby causing Edwardsiella septicemia. Acute Edwardsiella septicemia usually results in typical bacterial septicemia with a high mortality rate for fishes. Chronic Edwardsiella septicemia can result in Hole-in-the-head syndrome, septicemia or, ultimately, death.
  • Edwardsiella septicemia occurs worldwide and causes high mortality and considerable economic damage to the catfish industry, especially in Vietnam and the USA. Microbiological infections with E. ictaluri play a major role in catfish (Pangasianodon hypophthalmus) farming in Vietnam [Dung T T, et al., Microbe Drug Res 2008.] and were first observed in the Mekong River Delta in 1999 [Ferguson H W, et al. J Fish Dis 2001; 24:509-13]. E. ictaluri infections are seen in the USA in channel catfish (Ictalurus punctatus) and also in walking catfish in Thailand [Kasornchandra J, et al. J Fish Dis 1987; 10:137-8]. All catfish species are susceptible to E. ictaluri and the disease causes major damage in Basa Tra fish in the Mekong delta and other places where the fish is cultured in Vietnam. Many ways of protecting the fish have been tried but none so far have been very successful.
  • The use of antibiotics to counteract bacterial infections has been successful in some instances but not in others, especially because of widespread resistance as a result of extensive and non-controlled use of many different antibiotics either alone or in various combinations. The situation is worsened by the fact that E. ictaluri, and thus resistant E. ictaluri, can survive in the mud of a pond for up to 3 months. Furthermore, the use of antibiotics and chemotherapeutics is discouraged because of both environmental and residual problems, and long-term use of antibiotics is not a sustainable control method for fish diseases. However, preventing and protecting the fish from Edwardsiella septicemia cannot be achieved by using antibiotics which can only control the spreading of Edwardsiella septicemia.
  • Vaccination as a preventive measure to control infections with E. ictaluri has been tried in various catfish species. Until now, not a single vaccination or combination of vaccinations has been proven as particularly successful in the field. It has been claimed that an attenuated vaccine is able to help in the control of the disease but, to date, the product has not made major inroads in the field. Besides that, oral delivery of vaccine antigens to fish is the preferred method for several reasons. However the limitations of this method include lack of immune efficacy [Gudding R, et al. Vet Immunol Immunopathol 1999].
  • In view of the above-described disadvantages associated with conventional techniques, the inventor had developed a novel Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines.
    • SUMMARY OF THE INVENTION
  • The meaning of the technical and scientific terms as described herein can be clearly understood by the person skilled in the art.
  • One object of the invention is to provide a novel Edwardsiella ictaluri E-ict-VL33 strain, which had been identified as a novel strain of E. ictaluri.
  • Another object of the invention is to provide a vaccine, which is prepared from the inactivated E. ictaluri E-ict-VL33 strain. Said vaccine can be prepared as an immersion form, oral form or other suitable form.
  • Still another object of the invention is to provide a method for improving the immunity of fish against E. ictaluri, and further preventing and protecting fishes from infection of E. ictaluri by using said vaccines.
  • In order to achieve the above-described objects of the invention, the invention comprises various aspects as will be discussed below.
  • In one aspect of the invention, a novel E. ictaluri E-ict-VL33 strain is to be provided. This strain was isolated from infected tra catfish (Pangasius hypophthalmus). The isolated E-ict-VL33 strain has been cultured and identified as a novel E. ictaluri strain, named E. ictaluri E-ict-VL33, and deposited in the biological resource center ATCC Patent Depository, located at 10801 University Blvd., Manassas, Va. 20110 on Mar. 8, 2010, with an ATCC deposit number PTA-10711 and identification reference by deposit Edwardsiella ictaluri: E-ict-VL33. The bacterium strain of the invention has been used herein is an example, but the invention will not be limited thereto as all kinds of suitable strains are comprised in the invention.
  • In another aspect, the invention provides a vaccine composition comprising said novel E. ictaluri strain. In a preferred embodiment, said vaccine composition is a vaccine. The vaccine comprises an effective amount of inactivated E. ictaluri E-ict-VL33 strain and a pharmaceutically acceptable vehicle. It can be prepared in any dosage form suitable for the invention. Said suitable form of the invention includes, but is not limited to, oral-form, immersion-form, injection-form or other suitable forms for the invention.
  • An immersion vaccine is obtained by using an inactivating agent to inactivate or kill the E. ictaluri E-ict-VL33 strain (i.e., an inactivation process). The inactivated bacteria is then suspended in a buffer solution. This process allows an immersion vaccine to be obtained.
  • An oral vaccine is obtained by using an inactivating agent to inactivate or kill the Edwardsiella ictaluri E-ict-VL33 strain (i.e., an inactivation process). The inactivated bacteria is then suspended in a buffer solution to form a bacterial suspension, and the bacterial suspension is mixed with an adjuvant to form a mixture. The mixture is then homogenously emulsified by a homogenizer with high shear force. This process allows the oral vaccine to be obtained. Said oral vaccine can further be spray coated on the outside of a feed to deliver the oral vaccine to fish. Also, the coated feed can further be sprayed with edible oil, such as plant oil and/or animal oil (in particular, a fish oil), to improve the delivery efficiency of the oral vaccine.
  • The term “inactivation” as described herein includes, but is not limited to, treatment with inactivation agent, heat treatment, and other general methods to inactivate or kill the bacteria. The inactivation agent includes, but is not limited to, formaldehyde, binary ethyleneimine (BEI) or other suitable inactivation agents.
  • The pharmaceutically acceptable vehicle includes, but is not limited to, solvent, emulsifier, suspending agent, decomposer, binding agent, excipient, stabilizing agent, chelating agent, diluent, gelling agent, preservative, lubricant, surfactant, adjuvant or other suitable vehicle.
  • The adjuvant includes, but is not limited to, oleaginous adjuvant (such as mineral oil, plant oil, animal oil, Freund's Complete Adjuvant, Freund's Incomplete Adjuvant, etc.), aqueous adjuvant (such as aluminum hydroxide), two-phase oleaginous adjuvant (such as water/oil/water form (w/o/w)) etc, and biological (such as adjuvant oligonucleotide and toxoid). The two-phase oleaginous adjuvant comprises a surfactant and an oleaginous substance. The surfactant is selected from the group consisting of: at least one of sorbitol fatty acid ester, the concentrate of sorbitol fatty acid ester and ethylene oxide (or propylene oxide), mannitol fatty acid ester, the concentrate of mannitol fatty acid ester and ethylene oxide (or propylene oxide), modified mannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; anhydromannitol fatty acid ester, modified anhydromannitol fatty acid ester with a hydrophilic group which is selected from the group consisting of: at least one of carboxylic acid, amine, amide, alcohol, polyol, ether and oxide; saccharose fatty acid ester, the concentrate of saccharose fatty acid ester and ethylene oxide (or propylene oxide), glycerol fatty acid ester, the concentrate of glycerol fatty acid ester and ethylene oxide (or propylene oxide), the concentrate of fatty acid and ethylene oxide (or propylene oxide), the concentrate of fatty alcohol and ethylene oxide (or propylene oxide), and glycerophospholipid. The oleaginous substance is selected from the group consisting of: at least one of mineral oil, plant oil and animal oil. In a preferred embodiment, said oleaginous substance is animal oil, especially fish oil.
  • In addition, the invention also provides a composition comprising the novel E. ictaluri strain. The composition can be applied to various suitable products such as challenge composition containing live bacteria, vaccine containing inactivated bacteria etc.
  • In third aspect, the invention provides a method for improving the immunity of fishes against E. ictaluri, further preventing and protecting fishes from infection of E. ictaluri by using said vaccines. According to the following examples, a method comprising a primary immunization by immersion vaccination at first and, after an appropriate time period, a subsequent oral vaccination boosting, can give a protecting effect higher than would be obtained by other vaccination routes. Here, fishes refer to those that are susceptible to Edwardsiella ictaluri infection, in particular, catfishes. The invention also provides the use of Edwardsiella ictaluri E-ict-VL33 in preparation of a vaccine to protect fish from infection of Edwardsiella ictaluri.
  • The term “effective amount” refers to the amount of inactivated bacteria used to improve the immunity of fish against E. ictaluri, and then the amount of inactivated bacteria used to prevent and protect the fish from the infection of E. ictaluri or disease derived thereto in further inoculation.
  • The term “prevent and protect” is intended to mean that, compared to the immunity of untreated fish, the immunity of treated fish against E. ictaluri is improved and the survival rate of treated fish after infection of E. ictaluri is higher than survival rate of untreated fish. Further inoculation of the amount of inactivated bacteria prevents and protects the fish from the infection of E. ictaluri or disease derived thereto.
  • Further scope of the applicability of the present invention will become apparent from the detailed description given hereinafter. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The present invention will become more fully understood from the detailed description given hereinbelow and the accompanying drawings which are given by way of illustration only, and thus are not limitative of the present invention, and wherein:
  • FIG. 1 shows the morphology of the novel Edwardsiella ictaluri E-ict-VL33 strain under microscope.
  • FIG. 2 shows the cumulative mortality (%) obtained after challenge performed at 48 days post-vaccination using an immersion challenge in Groups A, C and E.
  • FIG. 3 shows the cumulative mortality (%) obtained after immersion challenge at 121 days post-primary immunization for Groups A, C, E and F.
    •  DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT
  • The invention will be illustrated by way of the following examples, but the invention will not be limited thereto.
    • Example 1 Isolation and Identification of Edwardsiella ictaluri E-ict-VL33 Strain
  • An isolated E-ict-VL33 strain was isolated from infected tra catfish (P. hypophthalmus). Bacterial culture grown in Brain Heart Infusion (BHI, the composition of BHI are shown in Table 1) broth for 18 hours at 25-30° C. was used for experimental infection. Bacteria growth on BHI agar for 48 h at 30° C. was used for bacterial identification.
  • TABLE 1
    The composition of BHI broth (Difco Laboratories, Sparks, MD)
    Composition Content
    Calf Brains, Infusion from 200 g  7.7 g
    Beef Heart, Infusion from 250 g  9.8 g
    Proteose Peptone 10.0 g
    Dextrose  2.0 g
    Sodium Chloride  5.0 g
    Disodium Phosphate  2.5 g
    Add water up to 1 liter
    Total   1 liter
  • The Characteristics of Edwardsiella ictaluri E-ict-VL33 Strain
  • FIG. 1 shows that the isolated E-ict-VL33 strain is a rod bacterium. An analysis of Gram staining shows that the isolated E-ict-VL33 strain is a Gram-negative rod bacterium. Referring to Tables 2 to 4, these tables show the growth situation of the isolated E-ict-VL33 strain under different culture conditions such as different temperature, salinity or pH value. “+” represents that the growth of bacteria is slower and contains a lower concentration of bacteria. “++” represents that the bacteria have grown with less precipitation. “+++” represents that the bacteria have grown with higher precipitation. “−” represents that there no growth of bacteria can be observed. In addition, the isolated E-ict-VL33 strain can be cultured in a tryptic soy broth (TSB) or a brain heart infusion (BHI). Furthermore, Table 5 shows the carbohydrate metabolism performance of the isolated E-ict-VL33 strain. “+” represents that the carbohydrate can be metabolized by the isolated E-ict-VL33 strain.
  • TABLE 2
    Culturing the isolated E-ict-VL33 strain
    at 28° C., under different pH values.
    pH value 4 5 6 7 8 9 10
    24 hr − + + ++ + + +
    48 hr − ++ +++ +++ +++ ++ ++
  • TABLE 3
    Culturing the isolated E-ict-VL33 strain under different temperatures.
    Temperature
    37° C. 37° C. (AC) 20° C. (AC) 20° C. 28° C.
    24 hr − + + − ++
    48 hr − +++ ++ − +++
    Note:
    “AC” stands for acclimatization. In a group labeled “AC,” the bacteria is cultured for about 2 day at 28° C., then cultured in a ratio of 1:100 at another temperature. The other groups (i.e., those not labeled “AC”) are colonies of bacteria incubated at different temperatures directly.
  • TABLE 4
    Culturing the isolated E-ict-VL33 strain at 28° C., under different salinity.
    Salinity
    0.5% 1% 1.5% 2%
    24 hr + + + −
    48 hr ++ ++ ++ −
  • TABLE 5
    The carbohydrate metabolism performance of the isolated E-ict-VL33
    strain.
    Carbohydrate Performance
    D-Fructose +
    Inosine +
    D-Psicose +
    Uridine +
    D-Galactose +
    α-D-Glucose +
    D,L-Lactic acid +
    D-Gluconic acid +
    N-acetyl-D-Glucosamine +
    L-Asparagine +
    Glycerol +
    D,L-α-Glycerol phosphate +
    Glycyl-L-Aspartic acid +
    D-Mannose +
    D-Glucose-6-Phosphate +
  • The Identification of Edwardsiella ictaluri E-ict-VL33 Strain
  • After a 16S rDNA analysis, the sequence of 16S rDNA of the isolated E-ict-VL33 strain is shown in SEQ ID No: 1. The result of the 16S rDNA analysis and the sequence alignment of the National Center for Biotechnology Information (NCBI) data bank was higher than 99% identified as E. ictaluri. This demonstrates that the isolated E-ict-VL33 strain is a member of E. ictaluri.
  • Because some E. ictaluri strains have a PEI1 plasmid, the inventor used the ORF1 (open reading frame 1) of the PEI1 plasmid (GenBank accession no: AF244083.1) of an E. ictaluri strain as a template to design PCR primers. Sequence of the PEI1 plasmid of the isolated E-ict-VL33 strain was determined by PCR using said primers. After sequencing, a partial sequence of the PEI1 plasmid of the isolated E-ict-VL33 strain is shown in SEQ ID No: 2 (the length of SEQ ID No: 2 is 1876 bp). In a sequence alignment comparing the sequence of SEQ ID NO: 2 with the NCBI data bank, the result indicates that the fragment of the 1st nucleotide (nt) to the 1443rd nt of SEQ ID NO: 2 is similar with the sequence of the PEI1 plasmid (GenBank accession no: AF244083.1) with 99% identity. However, the fragment of the 1444th nt to the 1876th nt of SEQ ID NO: 2 is different from the sequence of the PEI1 plasmid (GenBank accession no: AF244083.1). This indicates that the isolated E-ict-VL33 strain is different from the E. ictaluri strain with the PEI1 plasmid (GenBank accession no: AF244083.1). Although the isolated E-ict-VL33 strain and the E. ictaluri strain with the PEI1 plasmid (GenBank accession no: AF244083.1) are both E. ictaluri, they are different strains according to the sequencing result. Therefore, the isolated E-ict-VL33 strain is a novel E. ictaluri isolated strain.
  • The result shows that the isolated Edwardsiella ictaluri E-ict-VL33 strain is identified as a novel Edwardsiella ictaluri strain, and the E-ict-VL33 strain has been deposited in the ATCC on Mar. 8, 2010, with an ATCC deposit number PTA-10711.
    • Example 2 Preparation of Vaccines
  • Step 1 Cultivation and Collection of the Bacteria
  • The bacteria (Edwardsiella ictaluri E-ict-VL33 strain) were cultured in Brain Heart Infusion (BHI) broth at 28° C. for 48 hours, then collected in a bacteria suspension.
  • Step 2 Inactivated Processes
  • Inactivation of bacteria was done by adding 37% formaldehyde at a final concentration of 0.5% (w/v) to the bacteria suspension obtained in Example 1, and incubating (shaking) the bacteria suspension with formaldehyde at 25° C., 70 rpm for a minimum of 24 hours (preferably 48 hours). The bacteria (Edwardsiella ictaluri E-ict-VL33 strain) have to be verified as being completely inactive by a test. The supernatant of the bacteria suspension containing the formaldehyde was separated by using centrifugation at 9000×g to remove the formaldehyde, then suspending the pellet in a buffer solution (such as distilled water, phosphate buffered saline (PBS)). Finally, the vaccine stock containing inactivated antigen can be obtained. The vaccine stock were stored at +4° C.
    • Example 3 Preparation of Immersion Vaccine of Edwardsiella ictaluri E-ict-VL33
  • Vaccine stock obtained in example 2 were prepared as immersion vaccine by suspending the vaccine stock in a buffer solution (such as sterile water or PBS). The content of formaldehyde in the immersion vaccine is lower than 0.2% (v/v).
    • Example 4 Preparation of Oral Vaccine of Edwardsiella ictaluri E-ict-VL33
  • Vaccine stock obtained in example 2 were prepared as a 400 liter oral vaccine by mixing 300 liters of vaccine stock (at least comprising 1.65×1015 cfu bacteria), 4 liters of surfactant (polysorbate 80), and 96 liters of fish oil. The antigen of E. ictaluri was coated with a two phase oleaginous adjuvant in a w/o/w form by homogenously emulsifying the mixture with a homogenizer with high shear force (10,000 rpm). The oral vaccine can then be obtained. The 400 liter oral vaccine is composed of 24% (v/v) fish oil, 1% (v/v) surfactant, and 3.85×108 cfu/ml inactivated bacteria. The content of formaldehyde in the oral vaccine is lower than 0.2% (v/v).
  • Use of the Oral Vaccine
  • The invention also provides the application of the oral vaccine obtained in example 4. The oral vaccine can further be spray coated on the outside of commercially available pelleted feed at 2% (volume/weight). Also, the coated pellet can further be sprayed with squid oil at 0.1% (v/w). The feed can be AQUAXCEL 7434 pelleted feed or other commercially available feed.
    • Example 5 Efficiency of the Edwardsiella ictaluri E-ict-VL33 Inactivated Vaccine
  • 5-1. Efficiency Experiment
  • Healthy, non-infected, catfish (P. hypophthalmus), locally referred to as Tra fish, were vaccinated using immersion or oral vaccination or combinations of these vaccinations. The various vaccinations or vaccination combinations and challenge preparation were divided into various experiments for the (sub) groups. The various vaccinations or vaccination combinations and challenges were performed in at least 3 different experiments.
  • Experiment 1: Set Up the Challenge Model
  • A total of about 1500 fish were used to set up the challenge model to be used in the trial.
  • Bath challenge: Fifty fish per tank in three parallel tanks per dose (with 4 doses total) were challenged by pouring bacteria grown in BHI broth into water to give a final concentration of 5.5×103 to 5.5×106 colony forming units (5.5×103, 5.5×104, 5.5×105 and 5.5×106) of E. ictaluri E-ict-VL33 strain per ml of water. Exposure to the challenge dose lasted for 30 min. Strong aeration was supplied to the water in the tanks during the challenge. The control groups were immersed in clean aerated water. Mortalities were monitored for 14 days.
  • Injection challenge: Before injecting, fish were anaesthetized with 0.2% MS222 in the water. Fish were injected intraperitoneally with 0.1 ml of a bacterial dilution at 4 different bacterial concentrations ranging from 5.5×103 to 5.5×106 colony forming units (10-fold steps, 5.5×103, 5.5×104, 5.5×105 and 5.5×106) of E. ictaluri per ml or sterile saline water for control. Mortalities were monitored for 14 days.
  • From both experiments, moribund and freshly dead fish were submitted for bacterial isolation from the liver, spleen and kidney. Surviving fish at the end of monitoring period were checked for bacterial infection.
  • Experiment 2: Immersion/Oral Immunization Studies
  • Combined immersion/oral immunization studies are summarized in Table 6. The groups included Group A (immersion-prime) with immunization by immersion only (day 1) and challenge at 48 and 121 days after primary vaccination, Group C (imm-oral boost-1) with combined immersion (day 1) and oral boost by days 8 to 21, and Group F (imm-oral boost-2) boosted a second time through experimental days 101 to 107. Group E (oral-prime) was given primary immunization at days 8 to 21 by the oral route and challenged at 48 and 121 days after primary vaccination. Non-vaccinated control groups were challenged at 48 and 121 days.
  • Table 6 outlines how the immersion and oral vaccination of the various fish was done and which groups were challenged using the method established in Experiment 1.
  • Challenge Challenge
    Number at day 48 at day 121
    of primary first second (50 fish per (40 fish per
    Group replicates vaccination boost boost parallel) parallel)
    A 3 Immersion-prime — — Yes —
    1 Immersion-prime — — — Yes
    C
    3 Immersion-prime Oral — Yes —
    (day 8-21)
    1 Immersion-prime Oral — — Yes
    (day 8-21)
    F 1 Immersion-prime Oral Oral — Yes
    (day 8-21) (day 101-107)
    E 3 Oral — — Yes —
    (day 8-21)
    1 Oral — — — Yes
    (day 8-21)
    Ct 3 Non-vaccinated Yes —
    controls
    1 Non-vaccinated — Yes
    controls
    Note:
    Ct represents the control group and “—” represents the group without performing the treatment.
  • The process of immersion vaccination, oral vaccination, and immersion challenge are described as follow:
  • Immersion vaccination: The immersion vaccine consisted of a sterile water-based, killed bacterial suspension of 5.0×109 bacteria per ml Immersion vaccination was performed by immersing 1200 fish in 2 L of vaccine stock diluted in 18 L (5.56×108 bacteria per ml final concentration) of clean water for 1 min with strong aeration.
  • Oral vaccination: The outside of feed pellets was spray coated by the oral vaccine obtained in Example 4 (in a w/o/w form, containing 3.85×108 cfu/ml) at 2% (volume/weight). The coated pellets were then sprayed with squid oil at 0.1% (v/w). The coated feed pellets were prepared daily and used within 1 to 2 days after preparation and fed to satiation. The feed can be WOOSUNGVINA Co. J3, J4 feed or other commercially available feed.
  • Immersion challenge: The immersion challenge was performed in 96 liter tanks containing 70 liters of clean water. At the first challenge (day 48), 40 or 50 fish (number of fish depending on the experiment) from each tank were transferred to a bucket containing 10 liter of clean water and then bacteria grown in BHI broth was poured into the water to given concentrations of 7.6×106 or 4.3×106 bacteria/ml of water for Experiments 2 and 3, respectively. Exposure to the challenge dose lasted for 1 h. At the second challenge (121 days), the same immersion method was applied with a concentration of 8.1×106 bacteria/ml of water for Experiments 2. The non-challenged controls were immersed in clean aerated water. After challenge the fish were observed for 14 days.
  • Statistical Analysis
  • Fisher's exact test was used to analyze differences between groups at end-point. A P-value below 0.05 was considered to represent significant differences between groups/treatments.
  • 5-2. Results
  • Experiment 1
  • In this experiment, challenge by immersion was compared with challenge by injection. For immersion challenge the end-point mortality varied from 1.3% (±1.15 SD) at 5.5×103 cfu/ml to 66% (±8.5 SD) at 5.5×106 cfu/ml. For the injection challenge, it ranged from 93 (±1.5 SD) to 99.3% (±0.6 SD) end-point mortality over the dose range tested. Based on these results, immersion challenge was used for assessing vaccination efficacy and it was considered that the immersion dose of >106 gave sufficient mortality, i.e. more than 60% control mortality.
  • Experiment 2
  • Referring to FIG. 2 and Table 7, immersion/oral immunization studies (Experiment 2) showed a cumulative mortality in the non-vaccinated controls of 87% by day 48. In Group A (immersion-prime) the average cumulative mortality was 65% (±3.1 S.D.) (p<0.02), while in Group E (oral prime) average, cumulative mortality was 74%±3.5 (p>0.1), and in Group C (imm-oral boost-1) average cumulative mortality was 42%±4.0, (p<0.001), giving RPS values of 25, 15, and 52, respectively. The results indicate clearly that the fish given a combination of immersion and oral boost (C group) were much better protected than the fish in the other groups (A or E group).

  • Relative Percent Survival(RPS)=(1−(% mortality in vaccinated fish/% mortality in control))×100.
  • TABLE 7
    Cumulated mortality of the vaccinated and control fish in experiment 2 at
    first challenge (experiment day 48; 27 days post completion of oral boost).
    Vaccination method/group
    Immersion Immersion/oral
    Days after (only) (1x) Oral (only) Control
    challenge A1 A2 A3 C1 C2 C3 E1 E2 E3 Ct1 Ct2 Ct3
    1 0 0 0 0 0 0 0 0 0 0 0 0
    2 0 0 0 0 0 0 0 0 0 0 0 0
    3 0 0 0 0 0 0 0 0 0 0 0 0
    4 0 0 0 0 0 0 0 0 0 0 0 0
    5 0 0 0 0 0 0 0 0 0 0 0 0
    6 1 0 0 0 0 1 1 2 0 0 0 0
    7 4 0 3 2 1 4 3 3 4 7 6 3
    8 9 6 7 4 3 4 6 10 6 10 10 6
    9 11 7 4 6 5 6 10 7 11 6 12 9
    10 5 8 5 5 4 5 8 4 12 7 6 12
    11 3 4 9 1 3 2 5 4 1 7 4 5
    12 1 5 5 1 1 0 2 5 4 1 2 7
    13 0 1 0 2 1 1 3 0 0 3 2 0
    14 0 0 0 0 1 0 0 0 0 2 2 2
    Total mortality 34 31 33 21 19 23 38 35 38 43 44 44
    No. of fish/tank 50 50 50 50 50 50 50 50 50 50 50 50
    Mortality (%) 68 62 66 42 38 46 76 70 76 86 88 88
    Average mortality 65% 42% 74% 87%
    RPS 25   52   15   —
  • Referring to FIG. 3 and Table 8, the second challenge was performed at Experimental day 121 and fish were given a challenge dose of 8.1×106 cfu/ml of water. Cumulated mortality in the different vaccine groups and the control fish is shown in Table 10. At experimental day 121 the cumulative mortality in the controls was 90%. In Group A (immersion-prime) cumulative mortality was 80% (RPS=11, p=0.26), while Group E (oral prime) showed a mortality of 82% (RPS=9, p=0.388). In Group C (imm-oral boost-1) mortality was 64% (RPS=29, p=0.0037) while in Group F (imm-oral boost-2) cumulative mortality was 48% (RPS=47, p=0.0001). From the statistical evaluation only a combined vaccination of immersion/oral gives significant protection over the controls and single immunization procedures.
  • TABLE 8
    Cumulated mortality of the vaccinated and control fish in experiment 2 at
    second challenge (experiment day 121).
    Vaccination regimes/Group
    Immersion/oral
    Immersion/ (2 boost; 21
    Days after Immersion oral (21 d) Oral Controls day and 107*)
    challenge A C E Ct F
    1 0 0 0 0 0
    2 0 0 0 0 0
    3 0 0 0 0 0
    4 0 0 1 1 0
    5 1 2 3 3 1
    6 3 3 2 1 2
    7 3 3 5 4 2
    8 8 5 8 13 5
    9 10 7 10 9 7
    10 5 5 5 4 4
    11 5 5 4 3 2
    12 4 2 1 3 1
    13 1 0 2 2 0
    14 0 0 0 2 0
    Total 40 32 41 45 24
    mortality
    Total
    50 50 50 50 50
    number of
    fish/tank
    Mortality
    80 64 82 90 48
    (%)
    RPS 11 29 9 — 47%
    *the numbers indicate the experiment days that the oral boost feeding ended
  • The results show that a single immersion or oral immunization regime confers low protective immunity at long term post immunization. A combination of immersion and one oral boost is superior to the immersion (only) method. A second boost initiated 80 days after the first boost and completed 21 days before challenge resulted in an increased level of protection and gives a RPS=47 at a control mortality of 90%.
  • Together these findings show that a primary immunization with combined immersion and oral delivery induces a strong and long-lasting immunity Immunized fish benefit significantly from a second boost via the oral route.
  • In summary, the invention provides:
  • 1. A novel Edwardsiella ictaluri E-ict-VL33 strain.
  • 2. Vaccines derived from the novel Edwardsiella ictaluri E-ict-VL33 strain.
  • 3. A method for improving the immunity of fishes against Edwardsiella ictaluri, further preventing and promoting fishes from the infection of Edwardsiella ictaluri.
  • Many changes and modifications in the above described embodiment of the invention can, of course, be carried out without departing from the scopes thereof. Accordingly, to promote the progress in science and the useful arts, the invention is disclosed and is intended to be limited only by the scope of the appended claims.

Claims (4)

1. A method for improving fish immunity against Edwardsiella ictaluri comprising:
administering an Edwardsiella ictaluri vaccine composition to fish by immersion for primary immunization; and then administering the vaccine composition to fish by oral delivery for boost immunization.
2. A method as recited in claim 1, wherein the Edwardsiella ictaluri vaccine composition comprises an Edwardsiella ictaluri E-ict-VL33 strain which is ATCC deposit number PTA-10711, and wherein the Edwardsiella ictaluri vaccine composition is prepared from the inactivation of the Edwardsiella ictaluri E-ict-VL33 strain by inactivation agent.
3. A method as recited in claim 1, wherein before the Edwardsiella ictaluri vaccine composition is administered to fish by oral delivery, the vaccine composition can be spray-coated on the outside of a feed, and then the coated feed can further be sprayed with a oleaginous substance to obtain a feed coated by the vaccine composition.
4. A method as recited in claim 3, wherein the oleaginous substance is at least one selected from the group consisting of: mineral oil, plant oil and animal oil.
US13/050,453 2010-07-29 2011-03-17 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines Expired - Fee Related US8114411B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US13/050,453 US8114411B1 (en) 2010-07-29 2011-03-17 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
US13/314,724 US8545852B2 (en) 2010-07-29 2011-12-08 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/845,965 US8057805B1 (en) 2010-07-29 2010-07-29 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
US13/050,453 US8114411B1 (en) 2010-07-29 2011-03-17 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US12/845,965 Division US8057805B1 (en) 2010-07-29 2010-07-29 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/314,724 Division US8545852B2 (en) 2010-07-29 2011-12-08 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Publications (2)

Publication Number Publication Date
US20120027836A1 true US20120027836A1 (en) 2012-02-02
US8114411B1 US8114411B1 (en) 2012-02-14

Family

ID=44906878

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/845,965 Expired - Fee Related US8057805B1 (en) 2010-07-29 2010-07-29 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
US13/050,453 Expired - Fee Related US8114411B1 (en) 2010-07-29 2011-03-17 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
US13/314,724 Expired - Fee Related US8545852B2 (en) 2010-07-29 2011-12-08 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/845,965 Expired - Fee Related US8057805B1 (en) 2010-07-29 2010-07-29 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/314,724 Expired - Fee Related US8545852B2 (en) 2010-07-29 2011-12-08 Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Country Status (1)

Country Link
US (3) US8057805B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170330670A1 (en) * 2016-05-13 2017-11-16 Wally E. Rippel Liquid cooled magnetic element

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8057805B1 (en) * 2010-07-29 2011-11-15 Schweitzer Biotech Company Ltd. Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
ES2828873T3 (en) * 2013-06-28 2021-05-27 Aquilon Cyl S L Swine dysentery vaccine
US10188715B2 (en) 2013-06-28 2019-01-29 Aquilon Cyl Sociedad Limitada Swine dysentery vaccine
CN114561474A (en) * 2021-12-02 2022-05-31 华南农业大学 Molecular marker related to bacterial septicemia resistance of silurus meridionalis and application of molecular marker

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8057805B1 (en) * 2010-07-29 2011-11-15 Schweitzer Biotech Company Ltd. Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170330670A1 (en) * 2016-05-13 2017-11-16 Wally E. Rippel Liquid cooled magnetic element

Also Published As

Publication number Publication date
US8057805B1 (en) 2011-11-15
US20120076824A1 (en) 2012-03-29
US8545852B2 (en) 2013-10-01
US8114411B1 (en) 2012-02-14

Similar Documents

Publication Publication Date Title
KR101315092B1 (en) Immunogenic compositions comprising Lawsonia intracellularis
JP5229637B2 (en) Salmonella vaccine
US8545852B2 (en) Edwardsiella ictaluri E-ict-VL33 strain, vaccines thereof, and a method for protecting fishes using said vaccines
US7794730B2 (en) Polyvalent attenuated live vaccine for preventing and curing vibriosis of cultivated fish
CN1612749A (en) Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
EP2411047A1 (en) Vaccine for protection against streptococcus suis bacteria of various serotypes
US6585981B1 (en) Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
Thinh et al. Combined immersion and oral vaccination of Vietnamese catfish (Pangasianodon hypophthalmus) confers protection against mortality caused by Edwardsiella ictaluri
EP2569007B1 (en) Vaccine against mycoplasma hyopneumoniae, suitable for administration in the presence of maternally derived antibodies
US8431138B2 (en) In ovo vaccination of Campylobacter in avian species
EP2912198B1 (en) Immunogenic composition against aeromonas hydrophila
Gudmundsdóttir et al. Evaluation of cross protection by vaccines against atypical and typical furunculosis in Atlantic salmon, Salmo salar L.
Amen et al. Evaluating the efficacy of commercial Escherichia coli killed vaccine in broiler chickens
TW200843789A (en) Vaccine against fish-pathogenic bacteria
US7067122B1 (en) Modified live Edwardsiella tarda vaccine for aquatic animals
KR101209964B1 (en) Vaccine composition for swine polyserositis and manufacturing method thereof
US7988977B2 (en) Modified live Aeromonas hydrophila vaccine for aquatic animals
US6991793B2 (en) Method of protecting fish against columnaris disease with modified live Flavobacterium columnare
TWI403580B (en) The new Edwardsi strain E-ict-VL33 ( Edwardsiella ictaluri E-ict-VL33), its vaccine, and methods of using the vaccine to protect fish
Coaguila-Dávila et al. Experimental vaccination against Aeromonas hydrophila in Colossoma macropomum: Bacterial characterization, lethal doses, and mortality
KR101976764B1 (en) Tenacibaculum maritimum virulence attenuation technique and live attenuated vaccine for preventing fish Tenacibaculosis disease
US6153202A (en) In ovo methods for utilizing live Edwardsiella ictaluri against enteric septicemia in channel catfish
KR102606461B1 (en) Vaccine composition containing novel type of inactivated Salmonella Enteritidis whole cells for preventing or treating salmonellosis
KR20120039115A (en) Vaccine composition for swine polyserositis and manufacturing method thereof
KR20210146595A (en) Vaccine composition for preventing against infectious coryza and method for preparation thereof

Legal Events

Date Code Title Description
ZAAA Notice of allowance and fees due

Free format text: ORIGINAL CODE: NOA

ZAAB Notice of allowance mailed

Free format text: ORIGINAL CODE: MN/=.

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: SBC VIRBAC LIMITED, HONG KONG

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SCHWEITZER BIOTECH COMPANY LTD.;REEL/FRAME:033239/0001

Effective date: 20140613

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: 7.5 YR SURCHARGE - LATE PMT W/IN 6 MO, LARGE ENTITY (ORIGINAL EVENT CODE: M1555); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20240214